- Home
- OVLY vs IMMP Comparison
OVLY vs IMMP Comparison
Compare OVLY & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVLY
- IMMP
- Stock Information
- Founded
- OVLY 1990
- IMMP 1987
- Country
- OVLY United States
- IMMP Australia
- Employees
- OVLY N/A
- IMMP N/A
- Industry
- OVLY Major Banks
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- OVLY Finance
- IMMP Health Care
- Exchange
- OVLY Nasdaq
- IMMP Nasdaq
- Market Cap
- OVLY 219.0M
- IMMP 251.8M
- IPO Year
- OVLY N/A
- IMMP N/A
- Fundamental
- Price
- OVLY $27.65
- IMMP $2.04
- Analyst Decision
- OVLY
- IMMP Buy
- Analyst Count
- OVLY 0
- IMMP 1
- Target Price
- OVLY N/A
- IMMP $7.00
- AVG Volume (30 Days)
- OVLY 8.9K
- IMMP 199.3K
- Earning Date
- OVLY 10-22-2025
- IMMP 10-10-2025
- Dividend Yield
- OVLY 2.16%
- IMMP N/A
- EPS Growth
- OVLY N/A
- IMMP N/A
- EPS
- OVLY 2.84
- IMMP N/A
- Revenue
- OVLY $79,783,000.00
- IMMP $3,306,742.00
- Revenue This Year
- OVLY N/A
- IMMP $16.82
- Revenue Next Year
- OVLY N/A
- IMMP N/A
- P/E Ratio
- OVLY $9.74
- IMMP N/A
- Revenue Growth
- OVLY 2.98
- IMMP 31.28
- 52 Week Low
- OVLY $22.70
- IMMP $1.32
- 52 Week High
- OVLY $32.24
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- OVLY 54.85
- IMMP 59.75
- Support Level
- OVLY $25.41
- IMMP $1.96
- Resistance Level
- OVLY $27.03
- IMMP $2.17
- Average True Range (ATR)
- OVLY 0.55
- IMMP 0.11
- MACD
- OVLY 0.15
- IMMP -0.01
- Stochastic Oscillator
- OVLY 83.90
- IMMP 33.33
About OVLY Oak Valley Bancorp (CA)
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.